The Breast
Volume 19, Issue 2 , Pages 128-132 , April 2010

Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

  • Monica Iorfida

      Affiliations

    • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 57489502; fax: +39 02 94379205.
    • ,
  • Vincenzo Bagnardi

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Statistics, University of Milan-Bicocca, Milan, Italy
    • Frontier Science and Technology Research Foundation, Southern Europe, Milan, Italy
    • ,
  • Alessandra Balduzzi

      Affiliations

    • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • ,
  • Silvia Dellapasqua

      Affiliations

    • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • ,
  • Anna Cardillo

      Affiliations

    • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • ,
  • Alberto Luini

      Affiliations

    • Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Mattia Intra

      Affiliations

    • Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Ida Minchella

      Affiliations

    • Medical Care Unit, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • ,
  • Paolo Veronesi

      Affiliations

    • Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Giuseppe Viale

      Affiliations

    • Division of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • University of Milan School of Medicine, Milan, Italy
    • ,
  • Aron Goldhirsch

      Affiliations

    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy
    • ,
  • Marco Colleoni

      Affiliations

    • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    • Department of Medicine, European Institute of Oncology Milan, via Ripamonti 435, Milan 20141, Italy

Received 28 August 2009 ,Revised 20 November 2009 ,Accepted 27 December 2009.

References 

  1. Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol. 2008;66:31–41
  2. Chan A. A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer. Ann Oncol. 2007;18:1152–1158
  3. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane Study. Cancer. 2007;110(5):965–972
  4. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13:1198–1207
  5. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Bachleitner-Hoffmann T, Locker GJ, et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat. 2007;102:375–381
  6. Catania C, Medici M, Magni E, Munzone E, Cardinale D, Adamoli L, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol. 2007;18:1969–1975
  7. Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802–808
  8. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6622–6628
  9. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesteron receptors. Ann Oncol. 2000;11:1057–1059
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  11. Kuerer HM, Newman LA, Smith TM, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  12. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–1044
  13. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–2608
  14. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19:465–472
  15. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–1934
  16. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19:3506–3515
  17. Albain KS. Adjiuvant chemo-endocrine therapy for breast cancer: combined or sequential?. The Breast. 2003;12:12
  18. Fersis N, Smyczek-Gargya B, Armeanu S, Gagulic E, Pantic L, Relakis K, et al. Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. Eur J Gynecol Oncol. 2004;25:45–50
  19. Torrisi R, Dellapasqua S, Ghisini R, Viale G, Veronesi P, Luini A, et al. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. The Breast. 2008;17:654–660
  20. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer. 2008;99:1564–1571
  21. D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, et al. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J. 2008;14:435–441
  22. Andre F, Chafika M, Cornelia L, Kau SW, Frye D, Green M, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;108:183–190
  23. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–3685
  24. Gianni L, Eiermann W, Semiglazov V, Manikhas G, Lluch A, Tjulandin S, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Cancer Res. 2009;69(Suppl. 2):Abstr 31
  25. Peitinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, et al. Hormone receptor and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008;19:2020–2025
  26. Shou J, Massarwesh S, Osbourne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2 cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–935
  27. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467–1472
  28. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p1875 protein expression in human breast cancer cell lines. Cancer Res. 1990;50:3947–3951
  29. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102:43–49
  30. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab prolongs progression free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S5;(Abstr 3)
  31. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–1388
  32. Locker AP, Birrelli K, Bell JA, Nicholson RI, Elston CW, Blamey RW, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol. 1992;18:224–229
  33. Urriticoechea A, Smith IE, Dowsett M. Proliferative marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–7220

PII: S0960-9776(10)00002-0

doi: 10.1016/j.breast.2009.12.011

The Breast
Volume 19, Issue 2 , Pages 128-132 , April 2010

Article Tools

* Image Usage & Resolution